Progress on the relationship between metformin and breast cancer
10.3969/j.issn.1000-8179.20140613
- VernacularTitle:二甲双胍与乳腺癌关系的研究进展
- Author:
Lan MU
;
Fang XING
;
Meng XIAO
;
Xin WANG
- Publication Type:Journal Article
- Keywords:
metformin;
breast cancer;
diabetes mellitus;
cancer;
risk
- From:
Chinese Journal of Clinical Oncology
2014;(21):1413-1415
- CountryChina
- Language:Chinese
-
Abstract:
Diabetes mellitus increases the risk of breast cancer and affects the prognosis of breast cancer patients. Metformin, an anti-diabetic drug, decreases blood glucose level and has a role in suppressing various cancers. In addition, metformin has a unique in-hibitory effect on breast cancer, i.e., it can inhibit breast cancer cells in vivo and in vitro. Moreover, metformin exerts its anti-tumor ef-fect on epidermal growth factor receptor 2 (HER-2) positive and monoclonal antibody trastuzumab-resistant breast cancer cell lines, breast cancer stem cells, and triple negative breast cancer cells. Metformin can reduce the risk of the breast cancer in patients with dia-betes, lower histologic grade, and increase expression of estrogen and progesterone receptors. Furthermore, metformin has certain effect on neo-adjuvant chemotherapy for breast cancer. This review aims to clarify the mechanism of metformin in restraining breast cancer based on basic and clinical study results.
